Dr. Robert A Galemmo is a creative medicinal chemist, scientific and managerial leader. Throughout his career, Dr. Galemmo has led teams responsible for multiple clinical and development candidates in ‘Big Pharma’ and biotech. He initiated the medicinal chemistry effort that led to the new factor Xa anti-coagulant Apixaban/Eliquis. He has broad therapeutic area experience including CNS, Oncology, Cardiovascular, Inflammation and Gastrointestinal. Dr. Galemmo is named as an inventor on over 40 patents and applications; he is the author of more than 50 scientific publications. Dr. Galemmo specializes in strategic planning, project leadership, rational drug design, lead generation, multi-parameter optimization, compound design for enhanced CNS exposure and intellectual property development.